[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609996":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":21,"centralContacts":31,"locations":37,"responsibleParty":145,"collaborators":21,"id":147,"slug":148,"hasResults":149,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":149,"sex":155,"minAge":156,"maxAge":21,"enrollmentInfo":157,"targetDuration":21,"studyType":160,"phases":161,"briefSummary":163,"conditions":164,"keywords":167,"overallStatus":70,"whyStopped":21,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":186},{"fullName":5,"class":6},"Alexion Pharmaceuticals, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Oral Corticosteroid Tapering Schedule","EXPERIMENTAL","During the tapering period, participant will follow an Oral Corticosteroid tapering schedule until OCS tapering is complete",[13,14,15],"Procedure: Oral Corticosteroid Tapering Schedule","Drug: Ravulizumab","Drug: Prednisone\u002FPrednisolone",[17,22,27],{"type":18,"name":9,"description":19,"armGroupLabels":20,"otherNames":21},"PROCEDURE","During the tapering period, participant will follow an Oral Corticosteroid tapering schedule as applicable to the participant. The oral corticosteroid (prednisone\u002Fprednisolone) is provided as per standard medical care.",[9],null,{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":21},"DRUG","Ravulizumab","Patients being treated with intravenous ravulizumab as part of their standard medical care.",[9],{"type":23,"name":28,"description":29,"armGroupLabels":30,"otherNames":21},"Prednisone\u002FPrednisolone","Participants will continue with or be switched to prednisone\u002Fprednisolone as per standard medical care.",[9],[32],{"name":33,"role":34,"phone":35,"phoneExt":21,"email":36},"Alexion Pharmaceuticals, Inc. (Sponsor)","CONTACT","1-855-752-2356","clinicaltrials@alexion.com",[38,52,60,69,79,88,98,108,116,124,134,137],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":21},"Research Site","NOT_YET_RECRUITING","Chicago","Illinois","60637","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-87.65005,41.85003,{"lat":50,"lon":49},{"facility":39,"status":40,"city":53,"state":42,"zip":54,"country":44,"countryCode":45,"cosmosGeoPoint":55,"geoPoint":59,"contacts":21},"Schaumburg","60173",{"type":47,"coordinates":56},[57,58],-88.08341,42.03336,{"lat":58,"lon":57},{"facility":39,"status":40,"city":61,"state":62,"zip":63,"country":44,"countryCode":45,"cosmosGeoPoint":64,"geoPoint":68,"contacts":21},"Neptune City","New Jersey","07753",{"type":47,"coordinates":65},[66,67],-74.02792,40.20011,{"lat":67,"lon":66},{"facility":39,"status":70,"city":71,"state":72,"zip":73,"country":44,"countryCode":45,"cosmosGeoPoint":74,"geoPoint":78,"contacts":21},"RECRUITING","Raleigh","North Carolina","27607",{"type":47,"coordinates":75},[76,77],-78.63861,35.7721,{"lat":77,"lon":76},{"facility":39,"status":40,"city":80,"state":81,"zip":82,"country":44,"countryCode":45,"cosmosGeoPoint":83,"geoPoint":87,"contacts":21},"Knoxville","Tennessee","37920",{"type":47,"coordinates":84},[85,86],-83.92074,35.96064,{"lat":86,"lon":85},{"facility":39,"status":40,"city":89,"state":21,"zip":90,"country":91,"countryCode":92,"cosmosGeoPoint":93,"geoPoint":97,"contacts":21},"Bochum","44789","Germany","DE",{"type":47,"coordinates":94},[95,96],7.21648,51.48165,{"lat":96,"lon":95},{"facility":39,"status":40,"city":99,"state":21,"zip":100,"country":101,"countryCode":102,"cosmosGeoPoint":103,"geoPoint":107,"contacts":21},"Milan","20122","Italy","IT",{"type":47,"coordinates":104},[105,106],12.59836,42.78235,{"lat":106,"lon":105},{"facility":39,"status":40,"city":109,"state":21,"zip":110,"country":101,"countryCode":102,"cosmosGeoPoint":111,"geoPoint":115,"contacts":21},"Naples","80131",{"type":47,"coordinates":112},[113,114],14.26811,40.85216,{"lat":114,"lon":113},{"facility":39,"status":40,"city":117,"state":21,"zip":118,"country":101,"countryCode":102,"cosmosGeoPoint":119,"geoPoint":123,"contacts":21},"Rome","00189",{"type":47,"coordinates":120},[121,122],12.51133,41.89193,{"lat":122,"lon":121},{"facility":39,"status":40,"city":125,"state":21,"zip":126,"country":127,"countryCode":128,"cosmosGeoPoint":129,"geoPoint":133,"contacts":21},"Ibaraki","305-8576","Japan","JP",{"type":47,"coordinates":130},[131,132],135.56828,34.81641,{"lat":132,"lon":131},{"facility":39,"status":40,"city":135,"state":21,"zip":136,"country":127,"countryCode":128,"cosmosGeoPoint":21,"geoPoint":21,"contacts":21},"Kitakyushu-shi","807-8555",{"facility":39,"status":40,"city":138,"state":21,"zip":139,"country":127,"countryCode":128,"cosmosGeoPoint":140,"geoPoint":144,"contacts":21},"Kumamoto","860-8556",{"type":47,"coordinates":141},[142,143],130.69181,32.80589,{"lat":143,"lon":142},{"type":146,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100609996","phase-4-a-study-to-investigate-ocs-tapering-in-adult-participants-with-generalized-myasthenia-gravis-treated-with-ravulizumab-100609996",false,"NCT07221838","A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab","OCTAGON: A Phase 4, Single Arm Study to Investigate Oral Corticosteroid Tapering in Adult Patients With Generalized Myasthenia Gravis Treated With Ravulizumab","OCTAGON","Inclusion Criteria:\n\n* Aged greater than 18 years and male or female\n* Clinical diagnosis of gMG\n* Receiving ravulizumab treatment prior to enrollment\n* Receipt of OCS therapy equivalent to a daily dose ≥ 7.5 mg of prednisone\u002Fprednisolone for ≥ 4 continuous weeks directly preceding enrollment\n* A participant of childbearing potential must have a negative highly sensitive pregnancy test (serum or urine, as required by local regulations) taken at Screening before OCS tapering begins.\n* Willing to sign informed consent\n\nExclusion Criteria:\n\n* Concurrent participation in an interventional clinical trial.\n* History of chronic hypoadrenalism (ie, Addison's disease).\n* Use of concomitant OCS for comorbid conditions other than gMG\n* Receipt of a biologic for gMG (e.g., efgartigimod, rozanolixizumab, inebilizumab, rituximab, intravenous immunoglobulin) within 5 half-lives of enrollment\n* Pregnant, breastfeeding, or intending to conceive during the course of the study","ALL","18 Years",{"count":158,"type":159},75,"ESTIMATED","INTERVENTIONAL",[162],"PHASE4","This is a prospective, multicenter single arm study designed to evaluate the effectiveness and safety of a predefined oral corticosteroids (OCS) tapering schedule to reduce OCS use in adult participants with acetylcholine receptor positive (AChR+) generalized myasthenia gravis (gMG) being treated with intravenous ravulizumab.",[165,166],"Generalized Myasthenia Gravis","gMG",[168,166,169,170,171,172,173,174,175,176],"Generalized myasthenia gravis","Glucocorticoid toxicity","Complement C5 inhibitor","Prednisone reduction","Cortisol monitoring","ravulizumab","corticosteroids","adrenal insufficiency","steroid sparing","2026-04-06",{"date":179,"type":180},"2026-04-09","ACTUAL",{"date":182,"type":180},"2026-03-04",{"date":184,"type":159},"2027-08-27",{"name":5,"class":6},12]